

## Title page

**Title of paper:** Identifying baseline clinical features of people with COVID-19

**Short title:** Characteristics of people with COVID-19

### **Authors and institution(s) of origin**

*D. Ferreira-Santos*

CINTESIS - Center for Health Technology and Services Research; Faculty of Medicine,  
University of Porto, Porto, Portugal

*P. Maranhão*

CINTESIS - Center for Health Technology and Services Research; Faculty of Medicine,  
University of Porto, Porto, Portugal

*M. Monteiro-Soares*

MEDCIDS - Departamento de Medicina da Comunidade Informação e Decisão em Saúde;  
Faculty of Medicine, University of Porto, Porto, Portugal

CINTESIS - Center for Health Technology and Services Research; Faculty of Medicine,  
University of Porto, Porto, Portugal

*on behalf of COVIDcids*

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## **Abstract**

*Objectives:* To describe baseline clinical characteristics of adult patients with COVID-19.

*Methods:* We conducted a scoping review of the evidence available at LitCovid, until March 23th, 2020, and selected articles that reported the prevalence of socio-demographic characteristics, symptoms and co-morbidities in adults with COVID-19.

*Results:* In total, 1 572 publications were published on LitCovid. We have included 56 articles in our analysis, with 89% conducted in China, and 75% contained inpatients. Three studies were conducted in North America and one in Europe. Participants' age ranged from 28 to 70 years, with balanced gender distribution. Proportion of asymptomatic cases were from 2 to 79%. The most common reported symptoms were fever [4-99%], cough [4-92%], dyspnoea/shortness of breath [1-90%], fatigue 4-89%], myalgia [3-65%], and pharyngalgia [2-61%], while regarding co-morbidities we found cardiovascular disease [1-40%], hypertension [0-40%] and cerebrovascular disease [1-40%]. Such heterogeneity impairs the conduction of meta-analysis.

*Conclusions:* The infection by COVID-19 seems to affect people in a very diverse manner and with different characteristics. With the available data it is not possible to clearly identify those at higher risk of being infected with this condition. Furthermore, the evidence from countries other than China is, at the day, too scarce.

**Key-words:** COVID-19; infection; symptoms; co-morbidities; review

## 1. Introduction

In December 2019, in Wuhan, Hubei Province, China, a cluster of patients with pneumonia of unknown cause was observed [1]. Later, it was found that a new coronavirus caused it. In February 2020, the World Health Organization (WHO) designated the new virus as SARS-Cov-2 and the disease as COVID-19. According to this organization, since the onset of this disease until March 27<sup>th</sup> 2020, SARS-Cov-2 has infected more than half a million people in 136 countries, leading to the death of 23 335 [2].

The identification of patients that might be infected is crucial, so that they can be adequately screened, treated and/or isolated. In fact, political and health measures have been taken, having in consideration what is supposed to be known about populations at risk (focusing on their baseline co-morbidities) and also identifying those that present a higher chance of being infected by COVID-19 (focusing on their clinical symptoms). However, clinical manifestations are highly variable and the quality of the evidence that underlies these strategies and decisions is frequently not known. We consider that the creation of a predictive model that could help identify those at higher risk of having COVID-19, built on their baseline clinical features (such as socio-demographic, symptoms and presence of co-morbidities), could help prioritize screening and therapeutic strategies. The first step to accomplishing such endeavour is to list the most pertinent variables to be included in such a model. For all this, we have conducted a scoping review to summarize and critically assess articles describing baseline characteristics of individuals infected with COVID-19.

## 2. Methods

### 2.1. *Search strategy and selection criteria*

To conduct this scoping review, we used the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist [3].

We have reviewed the evidence available on LitCovid [4] for original articles published until March 23<sup>rd</sup> 2020 in English, French, Italian, Spanish or Portuguese that reported the proportion of socio-demographic characteristics, symptoms and co-morbidities in adults with COVID-19.

LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus indexed and accessible through PubMed. This repository is considered the most comprehensive resource on the subject. We have excluded reviews, opinion articles, case series that included five or less patients, studies that included only pregnant women or children and clear data duplication studies.

## 2.2. *Data extraction*


Articles were selected by two of the authors independently (DFS and PM) having in consideration the selection criteria. Once the articles were selected, data were extracted (by one of the authors and checked by another) into an Excel spreadsheet and included the following information: date of publication, country of study conduction, method used to detect the presence of COVID-19, last date of participants' inclusion, type of population, setting, sample size, participants' age and gender, frequency of asymptomatic patients, and frequency of reported symptoms and co-morbidities. We have ordered the included studies by continent, country (by alphabetical order) and sample size (in decreasing order). Only symptoms and co-morbidities described by five or more studies were included in our tables. Those addressed by less than five studies were only described in the narrative synthesis.

## 3. Results

### 3.1. *Characterization of the included studies*

Until the defined date, there were 1 572 publications in LitCovid and 53 (3%) fulfilled the inclusion criteria. In total, 895 were opinion articles (57%), 50 (3%) had five or less participants included, and the remaining addressed other topics such as diagnostic or genetics. We have used the reference list of 46 (3%) retrieved review articles that had information on frequency of symptoms to identify new articles that were not included in LitCovid database. This procedure led to the inclusion of three additional references [5-7]. In total, we have included 56 studies, as we can see in Figure 1.

Figure 1. Articles' selection flow diagram



In Table 1, we can see that, from the included studies, 50 (89%) were from China. We were able to identify only two studies from United States of America (USA), one from Canada, one from Korea, one from Singapore and one multicentre study that included patients from Belgium, Finland, France, Germany, Italy, Russia, Spain and Sweden. No study from Africa or Australia was retrieved.

The reverse transcription-polymerase chain reaction (RT-PCR) was the method most commonly used to detect the presence of infection by COVID-19 (89%). Looking at the 51 studies that reported setting, two included patients that were seen in the Emergency department, two admitted patients into Intensive Care Unit due to COVID-19, four studies reported included outpatients, one incorporated outpatients and inpatients, while remaining (75%) included inpatients.

In total, 50 500 participants were included. However, one of the studies from China [8] contributed with 88% of the participants. Sample size ranged from 7 to 44 672 participants, with a median of 66 participants per study.

The median age ranged from 28 [9] to 70 [10]. Both studies were conducted in North America. When looking at studies from other continents, we observe a smaller range. In Asia, median age

varied from 33 [11] to 60 [12], and 42 in the European multicentre study [13]. There was a balance on gender distribution, with the male gender proportion ranging from 44 [9] to 55% [14] in North American studies, 26 [7] to 77% [15] in Asian studies and 55% in the European study [13]. In 57% of the studies, male gender was more prevalent.

Asymptomatic cases were reported in 10 studies (18%), with no available data for North America. In the European study [13], there were 24% of asymptomatic patients and in Asia it fluctuated from two [8, 16] to 79% [11].

### 3.2. *Symptoms*

The described symptoms were generally nonspecific and widely variable, ranging from asymptomatic to a rapid multi organ dysfunction as we can see from Tables 2 to 4.

Fever was one of the most reported symptoms. Its presence ranged from 48 [9] to 68% [14] in North America, 4 [17] to 99% [18] in Asia and 69% in the European study [13].

Fatigue was observed in 17% of the participants from the USA study [14] and ranged from four [19] to 89% [20] in studies from China. Myalgia was reported in 3% of the patients included in the European study [13]. In Chinese studies, it ranged from three [21] to 33% [22], and reached 65% [23] when combined with fatigue. Anorexia, chills and dizziness were registered only in Asian studies and their prevalence ranged from one [24] to 43% [7], one [25] to 42% [22] and two [24, 26] to 16% [27], respectively. Complaints of headache were described in the European study in 21% [13] of the patients and from zero [22] to 34% [6, 28] in two Chinese studies.

Malaise was present in 17% of the participants in one study from USA [9] and 35% in another study from Asia [29]. Weakness was reported in 28% of patients in the European study [13] and ranged from 9 [24] to 11% [30] in two studies from China. Malnutrition was present in two percent of the participants in one study [29]. Skin tingling was described but not quantified in one study [31]. Arthralgia was described in three studies, all conducted in China [25, 26, 29]. This symptom was reported in two percent of the sample in one study [29], and 15% [25] and 61% [26] in two studies that combined the presence of arthralgia or myalgia as one symptom.

The presence of pharyngalgia was reported in one study from USA [14], in 30% of the participants.. In studies from China the prevalence of this symptom varied from two [29] to 61% [32]. In the European study [13], both pharyngalgia and rhinorrhoea were reported by 7% of the participants. The later symptom ranged from two [29] to 26% [24] in Chinese patients. The frequency of nasal congestion and throat congestion was reported only in studies from China. In one study [25], two percent of the participants described feeling throat congestion, and nasal congestion varied from 5 [25] to 62% [15] in two studies.

From respiratory symptoms, cough was the most frequently assessed; one study from USA and European study reported to be present in 48% of the sample [10, 13]. Cough or dyspnoea were reported by 82% of the patients in one study from Canada [9] and 90% in the USA [14]. Specifically, productive cough, chest tightness and chest pain were registered only on studies from China and varied from 4 [33] to 56% [28], 5 [34] to 37% [35], and two [29] to 14% [27], respectively. In one study [27], 14% of patients reported feeling chest pain or dyspnoea.

The presence of dyspnoea alone was also described in the majority of the studies. One study from the USA reported its presence in 76% of the patients [10], while in the European study [13] it was only observed in 7% of the patients. As for the studies conducted in China, dyspnoea prevalence oscillated from one [21] to 64% [29].

General gastrointestinal symptoms were described by 10% [9] of the patients in one study from Canada and 40% [35] in another from China. From the gastrointestinal system, only diarrhoea and nausea were recorded in the European study [13]. Both presented a 3% prevalence. From the studies conducted in China, diarrhoea prevalence ranged from one [36] to 27% [37], nausea from one [21, 36, 38] to 17% [22], vomit from one [29] to 18% [39] and abdominal distress from one [40] to 6% [35]. When combining abdominal pain or diarrhoea, the prevalence raised to 15% [41]. Belching or gastritis was recorded in only one study from China [35] and was reported by 5% of the patients. Irritability or confusion was documented in three [21] and 9% [38] of the patients included in two studies from China, and the presence of rash and enlargement of lymph nodes was assessed in only one study and was not found in any patient [25].

### 3.3. *Co-morbidities*

As we can see in Table 5, the presence of co-morbidities was not reported in the European study and only one of the studies from the USA had relevant information [10]. In this study, 86% of the patients had at least one comorbidity. The most frequent were chronic kidney disease (48%), congestive heart failure (43%), diabetes (33%), chronic obstructive pulmonary disease (33%) and obstructive sleep apnoea (29%). Less than 10% of the patients presented end-stage kidney disease, asthma, cirrhosis and rheumatologic disease.

The remaining data was from Asian studies, in which several concomitant infections were described. The presence of Hepatitis B was observed in one [42], two [17, 25] and 5% [34] of the participants in the four studies that described its frequency. Prevalence of human immunodeficiency virus was reported to be of zero [18, 26, 36] and 6% [23]. Only one study described bacterial co-infection in 17% of the patients [22].

Numerous studies described that some patients presented malignant diseases. This co-morbidity prevalence ranged from zero [42] up to 9% [23]. Only one study described the presence of thyroid disease [35] and other of hyperlipidaemia in four and 5% [35] of the participants, respectively. Two studies reported the presence of hypothyroidism in two [17] and 6% [23] of the patients. Various studies reported the prevalence of diabetes, with values ranging from 2 [43] up to 33% [44]. The presence of kidney disease ranged from one [8, 25, 44] up to 6% [19]; chronic kidney disease was observed in one [35] up to 17% [24] of the patients. Only one study reported the proportion of patients with renal insufficiency [22] and urolithiasis [35] to be of 17% and two percent, respectively. Chronic liver disease was observed in zero [22] to 11% [28] of the participants. Hepatic insufficiency was reported by two studies to have a prevalence of 9 [24] and 17% [22]. Fatty liver and abnormal liver function were observed in 6% of the patients in one study [35]. Digestive system diseases were described in four studies in four [42], 6 [16] and 11% [38] of the participants.

The presence of cerebrovascular disease was reported in several studies and ranged from one [25] to 31% [36] of the participants, reaching 40% [38] when combined with cardiovascular disease. Dementia was described in one study, with a value of two percent [29]. Nervous system diseases



were ascertained in three studies, with a frequency of one [36, 38] and three percent [45]. The same number of studies registered a history of stroke and observed its presence in two [35, 41] and 8% [22] of the participants.

Cardiovascular disease prevalence ranged from one [6, 27] to 33% [22] of the patients in the various studies reporting it. Hypertension frequency varied from zero [46] to 40% [47]. The presence of tachycardia was registered in four studies and reported to be of two [6], four [48] and 7% [33, 49]. We only found one study that described the prevalence of arrhythmia (with a value of four percent [35]), persistent atrial fibrillation (6% [39]), cardiac failure (8% [22]) or aorta sclerosis (1% [35]).

Various studies described the prevalence of baseline respiratory system conditions. Respiratory disease, in general, was found in one [36, 38] to 41% [12] of the patients, pulmonary disease to range between one [48] to 10% [49], and chronic obstructive pulmonary disease between zero (37, 47) and 33% [49] of the patients. We only found two studies that described the prevalence of asthma (with a value of two percent [17] up to 9% [10]), and one study describing a 6% of rhinitis [5].

#### **4. Discussion**

This is the first scoping review focusing on baseline characteristics of patients with COVID-19. Although our aim was to try to better identify those at higher risk of having the condition, only descriptive studies were found. We have identified 56 articles; two were conducted in USA, one in Canada and one was a multicentre European study. No studies from Africa, South America or Australia were retrieved. At the date of the end of our review, according to WHO [50], there were 25 375 cases of COVID-19 in the Region of the Americas, 171 424 in European Region and 990 in African Region.

As we can observe above, most of the studies were conducted in China, the first country in which COVID-19 was detected. Furthermore, one of these studies [8] contributed to 88% of the participants. This study consists of the Chinese Center for Disease Control and Prevention Report.

Therefore, we cannot be sure about how many of the other Chinese studies described results that are included in this report, representing duplicate participants.

We observed a very high heterogeneity on sample size, patients' age and described symptoms and co-morbidities. Accounting for this heterogeneity, we have considered that it was not adequate to conduct a meta-analysis and performed only a narrative synthesis of the available evidence. We also acknowledge the exclusion of articles written only in Chinese due to the fear of further data duplication [51].

In the included studies, the median age ranged from 28 to 70 years, being 50 years or less in 36 (72%) of the studies. Only one-fifth of the studies described the proportion of asymptomatic patients. In the European study, it was around 25% and in the Asian studies ranged from two up to 75% of the patients. It highlights the importance of wide screening and people isolation strategies due to the risk of being in contact with infected but asymptomatic people.

The prevalence of more than 30 symptoms and 35 co-morbidities were collected; however, several were reported by five or less studies. The most reported symptoms were fever, cough, dyspnoea, fatigue, myalgia and pharyngalgia. Cardiovascular disease, hypertension and cerebrovascular disease were the most reported comorbidities. However, this is also due to the commonly high prevalence of these diseases in the general population and the focus given to more severe cases by several studies.

There is a previous systematic review with meta-analysis of prevalence of symptoms and co-morbidities in people with COVID-19 that included eight studies published until February 5, 2020 [52]. The authors concluded that the most prevalent clinical symptoms were fever (with a pooled prevalence of 91%), cough (67%), fatigue (51%) and dyspnoea (30%). The most prevalent co-morbidities were hypertension (17%), diabetes (8%), cardiovascular diseases (5%) and respiratory system diseases (2%). However, the authors reported high levels of heterogeneity when pooling such prevalence ( $I^2$  ranged from 85 to 96%).

A more recent systematic review with meta-analysis to identify clinical, laboratory and imaging features of COVID-19, included studies until February 21, 2020 [53]. When pooling the 18 included studies, once again, fever (pooled prevalence of 88%), cough (58%) and dyspnoea were

the most common symptoms, and hypertension (19%), cardiovascular disease (14%) and diabetes (12%) the most frequent co-morbidities. Once again, severe heterogeneity was observed by the authors.

Our study, observed that the presence of fever ranged from four to 99%, cough from four to 92%, fatigue from four to 89% and dyspnoea from one to 90%; as for co-morbidities the prevalence of hypertension varied from zero to 40%, diabetes from 2 to 33% and cardiovascular disease from one to 40%. We highlight that these values cannot be directly compared between studies without having in consideration that they reflect the existence of different populations, healthcare settings, selection criteria and different times of the disease history. Such massive variation on the range of observed prevalence for all symptoms and co-morbidities impairs the selection of any of them as pertinent to be included in a predictive model to identify people at high risk of being infected with COVID-19.

We consider that future research conducted specifically with that aim and assessing the ability of several symptoms and/or co-morbidities combined to stratify people by their risk of being infected is crucial. Also, there is a great need for further studies conducted outside China so that comparisons can be made about baseline characteristics as well as clinical outcomes.

### **Acknowledgments**

The work from Daniela Ferreira-Santos was supported by Fundação para a Ciência e Tecnologia (FCT) [grant number PD/BD/13553/2018]. The work from Priscila Maranhão was supported by ODISSEIA - Oncology Information System project (POCI-05-5762-FSE-039021), financed by the North Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, and through the European Regional Development Fund (ERDF) and European Social Fund (ESF) respectively. The authors declare that they have no conflicts of interest. We also would like to acknowledge Professor Pedro Pereira Rodrigues and M.D. Ana Margarida Pereira, for a critical review of the manuscript.

### **Role of the funding source**

The institutions who provided financial support had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

## References

- [1] C. Wang, P. W. Horby, F. G. Hayden, and G. F. Gao, "A novel coronavirus outbreak of global health concern," (in eng), *Lancet*, vol. 395, no. 10223, pp. 470-473, Feb 15 2020, doi: 10.1016/s0140-6736(20)30185-9.
- [2] WHO, "Coronavirus disease 2019 (COVID 2019): situation report," vol. 67, 2020.
- [3] A. C. Tricco *et al.*, "PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation," *Annals of Internal Medicine*, vol. 169, no. 7, pp. 467-473, 2018, doi: 10.7326/m18-0850.
- [4] LitCovid. "LitCovid " <https://www.ncbi.nlm.nih.gov/research/coronavirus/> (accessed.
- [5] J. Li *et al.*, "Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China," *medRxiv*, p. 2020.02.11.20022053, 2020, doi: 10.1101/2020.02.11.20022053.
- [6] J. Liu *et al.*, "Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage," *medRxiv*, p. 2020.02.10.20021584, 2020, doi: 10.1101/2020.02.10.20021584.
- [7] F. Pan *et al.*, "Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia," (in eng), *Radiology*, p. 200370, Feb 13 2020, doi: 10.1148/radiol.2020200370.
- [8] Z. Wu and J. M. McGoogan, "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention," (in eng), *Jama*, Feb 24 2020, doi: 10.1001/jama.2020.2648.
- [9] M. Lin *et al.*, "What can early Canadian experience screening for COVID-19 teach us about how to prepare for a pandemic?," *CMAJ*, Mar 6 2020, doi: 10.1503/cmaj.200305.
- [10] M. Arentz *et al.*, "Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State," (in eng), *Jama*, Mar 19 2020, doi: 10.1001/jama.2020.4326.
- [11] Z. Hu *et al.*, "Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China," *Sci China Life Sci*, Mar 4 2020, doi: 10.1007/s11427-020-1661-4.
- [12] M. Yuan, W. Yin, Z. Tao, W. Tan, and Y. Hu, "Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China," *PLoS One*, vol. 15, no. 3, p. e0230548, 2020, doi: 10.1371/journal.pone.0230548.
- [13] G. Spiteri *et al.*, "First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020," (in eng), *Euro Surveill*, vol. 25, no. 9, Mar 2020, doi: 10.2807/1560-7917.Es.2020.25.9.2000178.

- [14] K. L. Bajema *et al.*, "Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020," (in eng), *MMWR Morb Mortal Wkly Rep*, vol. 69, no. 6, pp. 166-170, Feb 14 2020, doi: 10.15585/mmwr.mm6906e1.
- [15] D. Chang *et al.*, "Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China," (in eng), *Jama*, vol. 323, no. 11, pp. 1092-3, Feb 7 2020, doi: 10.1001/jama.2020.1623.
- [16] W. Zhao, Z. Zhong, X. Xie, Q. Yu, and J. Liu, "Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study," (in eng), *AJR Am J Roentgenol*, pp. 1-6, Mar 3 2020, doi: 10.2214/ajr.20.22976.
- [17] Y. Wang, Y. Liu, L. Liu, X. Wang, N. Luo, and L. Ling, "Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China," (in eng), *J Infect Dis*, Mar 17 2020, doi: 10.1093/infdis/jiaa119.
- [18] D. Wang *et al.*, "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China," *JAMA*, Feb 7 2020, doi: 10.1001/jama.2020.1585.
- [19] T. Xu *et al.*, "Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19," (in eng), *Int J Infect Dis*, Mar 13 2020, doi: 10.1016/j.ijid.2020.03.022.
- [20] C. Xie *et al.*, "Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests," (in eng), *Int J Infect Dis*, vol. 93, pp. 264-267, Feb 27 2020, doi: 10.1016/j.ijid.2020.02.050.
- [21] W. Yang *et al.*, "Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China," *J Infect*, vol. 80, no. 4, pp. 388-393, Apr 2020, doi: 10.1016/j.jinf.2020.02.016.
- [22] Y. Liu *et al.*, "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury," *Sci China Life Sci*, vol. 63, no. 3, pp. 364-374, Mar 2020, doi: 10.1007/s11427-020-1643-8.
- [23] Y. Huang *et al.*, "Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis," *Travel Med Infect Dis*, p. 101606, Feb 27 2020, doi: 10.1016/j.tmaid.2020.101606.
- [24] H. Shi *et al.*, "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study," (in eng), *Lancet Infect Dis*, vol. 20, no. 4, pp. 425-434, Apr 2020, doi: 10.1016/s1473-3099(20)30086-4.
- [25] W. J. Guan *et al.*, "Clinical Characteristics of Coronavirus Disease 2019 in China," *N Engl J Med*, Feb 28 2020, doi: 10.1056/NEJMoa2002032.
- [26] P. Mo *et al.*, "Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China," *Clin Infect Dis*, Mar 16 2020, doi: 10.1093/cid/ciaa270.

- [27] F. Song *et al.*, "Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia," (in eng), *Radiology*, vol. 295, no. 1, pp. 210-217, Apr 2020, doi: 10.1148/radiol.2020200274.
- [28] X. W. Xu *et al.*, "Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series," (in eng), *Bmj*, vol. 368, p. m606, Feb 19 2020, doi: 10.1136/bmj.m606.
- [29] X. Yang *et al.*, "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study," (in eng), *Lancet Respir Med*, Feb 24 2020, doi: 10.1016/s2213-2600(20)30079-5.
- [30] E. a. C. M. T. COVID-19 National Emergency Response Center, Korea Centers for Disease Control and Prevention, "Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea," (in eng), *Osong Public Health Res Perspect*, vol. 11, no. 1, pp. 8-14, Feb 2020, doi: 10.24171/j.phrp.2020.11.1.03.
- [31] T. Zhen-Dong *et al.*, "Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020," *Emerging Infectious Disease journal*, vol. 26, no. 5, 2020, doi: 10.3201/eid2605.200198.
- [32] B. E. Young *et al.*, "Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore," (in eng), *Jama*, Mar 3 2020, doi: 10.1001/jama.2020.3204.
- [33] K. Liu *et al.*, "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province," *Chin Med J (Engl)*, Feb 7 2020, doi: 10.1097/CM9.0000000000000744.
- [34] D. Zhao *et al.*, "A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias," *Clin Infect Dis*, Mar 12 2020, doi: 10.1093/cid/ciaa247.
- [35] J. J. Zhang *et al.*, "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China," *Allergy*, Feb 19 2020, doi: 10.1111/all.14238.
- [36] J. Wu *et al.*, "Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study," *Clin Infect Dis*, Feb 29 2020, doi: 10.1093/cid/ciaa199.
- [37] C. Qin *et al.*, "Dysregulation of immune response in patients with COVID-19 in Wuhan, China," (in eng), *Clin Infect Dis*, Mar 12 2020, doi: 10.1093/cid/ciaa248.
- [38] N. Chen *et al.*, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study," (in eng), *Lancet*, vol. 395, no. 10223, pp. 507-513, Feb 15 2020, doi: 10.1016/s0140-6736(20)30211-7.
- [39] K. Liu, Y. Chen, R. Lin, and K. Han, "Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients," (in eng), *J Infect*, Mar 27 2020, doi: 10.1016/j.jinf.2020.03.005.

- [40] G. Q. Qian *et al.*, "Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series," (in eng), *Qjm*, Mar 17 2020, doi: 10.1093/qjmed/hcaa089.
- [41] S. Zhou, Y. Wang, T. Zhu, and L. Xia, "CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China," (in eng), *AJR Am J Roentgenol*, pp. 1-8, Mar 5 2020, doi: 10.2214/ajr.20.22975.
- [42] J. Chen *et al.*, "Clinical progression of patients with COVID-19 in Shanghai, China," (in eng), *J Infect*, Mar 19 2020, doi: 10.1016/j.jinf.2020.03.004.
- [43] C. Wu *et al.*, "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China," (in eng), *JAMA Intern Med*, Mar 13 2020, doi: 10.1001/jamainternmed.2020.0994.
- [44] F. Zhou *et al.*, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study," (in eng), *Lancet*, vol. 395, no. 10229, pp. 1054-1062, Mar 28 2020, doi: 10.1016/s0140-6736(20)30566-3.
- [45] W. Zhu, K. Xie, H. Lu, L. Xu, S. Zhou, and S. Fang, "Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China," *Journal of Medical Virology*, vol. n/a, no. n/a, doi: 10.1002/jmv.25763.
- [46] N. Tang, D. Li, X. Wang, and Z. Sun, "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia," *J Thromb Haemost*, vol. 18, no. 4, pp. 844-847, Apr 2020, doi: 10.1111/jth.14768.
- [47] W. Liu *et al.*, "Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease," *Chin Med J (Engl)*, Feb 28 2020, doi: 10.1097/CM9.0000000000000775.
- [48] S. Wan *et al.*, "Clinical features and treatment of COVID-19 patients in northeast Chongqing," (in eng), *J Med Virol*, Mar 21 2020, doi: 10.1002/jmv.25783.
- [49] Z. Wang, B. Yang, Q. Li, L. Wen, and R. Zhang, "Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China," *Clin Infect Dis*, Mar 16 2020, doi: 10.1093/cid/ciaa272.
- [50] WHO. "Coronavirus disease 2019 (COVID-19). Situation Report – 63." [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200323-sitrep-63-covid-19.pdf?sfvrsn=d97cb6dd\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200323-sitrep-63-covid-19.pdf?sfvrsn=d97cb6dd_2) (accessed).
- [51] B. Li *et al.*, "Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China," (in eng), *Clin Res Cardiol*, pp. 1-8, Mar 11 2020, doi: 10.1007/s00392-020-01626-9.
- [52] J. Yang *et al.*, "Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis," (in eng), *Int J Infect Dis*, Mar 12 2020, doi: 10.1016/j.ijid.2020.03.017.



- [53] A. J. Rodriguez-Morales *et al.*, "Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis," *Travel Medicine and Infectious Disease*, p. 101623, 2020/03/13/ 2020, doi: <https://doi.org/10.1016/j.tmaid.2020.101623>.
- [54] S. Tian *et al.*, "Characteristics of COVID-19 infection in Beijing," *J Infect*, vol. 80, no. 4, pp. 401-406, Apr 2020, doi: 10.1016/j.jinf.2020.02.018.
- [55] A. Bernheim *et al.*, "Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection," (in eng), *Radiology*, p. 200463, Feb 20 2020, doi: 10.1148/radiol.2020200463.
- [56] R. Han, L. Huang, H. Jiang, J. Dong, H. Peng, and D. Zhang, "Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia," (in eng), *AJR Am J Roentgenol*, pp. 1-6, Mar 17 2020, doi: 10.2214/ajr.20.22961.
- [57] K. Li *et al.*, "The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia," (in eng), *Invest Radiol*, Feb 29 2020, doi: 10.1097/rli.0000000000000672.
- [58] X. Xu *et al.*, "Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2," (in eng), *Eur J Nucl Med Mol Imaging*, vol. 47, no. 5, pp. 1275-1280, May 2020, doi: 10.1007/s00259-020-04735-9.
- [59] K. C. Liu *et al.*, "CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity," (in eng), *Eur J Radiol*, vol. 126, p. 108941, Mar 12 2020, doi: 10.1016/j.ejrad.2020.108941.
- [60] Y. Xiong *et al.*, "Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes," (in eng), *Invest Radiol*, Mar 3 2020, doi: 10.1097/rli.0000000000000674.
- [61] C. Huang *et al.*, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China," (in eng), *Lancet*, vol. 395, no. 10223, pp. 497-506, Feb 15 2020, doi: 10.1016/s0140-6736(20)30183-5.
- [62] M. Chung *et al.*, "CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)," *Radiology*, vol. 295, no. 1, pp. 202-207, Apr 2020, doi: 10.1148/radiol.2020200230.
- [63] Z. Cheng *et al.*, "Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China," (in eng), *AJR Am J Roentgenol*, pp. 1-6, Mar 14 2020, doi: 10.2214/ajr.20.22959.
- [64] X. Dong *et al.*, "Eleven faces of coronavirus disease 2019," (in eng), *Allergy*, Mar 20 2020, doi: 10.1111/all.14289.

Table 1. Characterization of the included studies [ordered by continent, country (by alphabetical order) and sample size (in decreasing order)]

	Ref	Country of data collection	COVID-19 detection method	Date of end of inclusion	Population	Setting	Sample size (n)	Age (median)	Male (%)	Asymptomatic patients (%)	
America (North)	[9]	Canada	RT-PCR	2020-02-19	Adult	ED	135	28	44		
	[14]	USA	CDC criteria	2020-02-04	Adult/Children	Inpatient & Outpatient	210	29	55	ND	
	[10]	USA	RT-PCR	2020-03-05	Adult	ICU	21	70	52		
<b>Range</b>		-	-	-	-	-	<b>[21-210]</b>	<b>[28-70]</b>	<b>[44-55]</b>	-	
Asia	[8]	China	RT-PCR	2020-02-11	Adult/Children	ND	44 672	ND	ND	2	
	[25]			2020-01-31	Adult/Children	Inpatient	1 099	47	58		
	[37]			2020-02-12	ND	Inpatient	452	58	52	ND	
	[54]			ND	Adult/Children	Inpatient	262	48	49		
	[42]			2020-02-06		Inpatient	249	51	51	3	
	[43]			2020-02-13		Inpatient	201	51	64		
	[44]			2020-01-31		Inpatient	191	56	62		
	[46]			2020-02-13		Inpatient	185	54	54		
	[26]			2020-02-05		Inpatient	155	54	56		
	[21]			2020-02-10		Inpatient	149	45	54		
	[35]			2020-02-03	Adult	Inpatient	140	57	51	ND	
	[18]			2020-01-28		Inpatient	138	56	54		
	[33]			2020-01-24		Inpatient	137	57	45		
	[48]			2020-02-08		Inpatient	135	47	53		
	[55]			2020-02-02		Inpatient	121	45	50		
	[56]			2020-02-03		Inpatient	108	45*	35		
	[16]			ND		Inpatient	101	44*	55	2	
	[38]			2020-01-20		Inpatient	99	55*	68		
	[40]			2020-02-11	Adult/Children	Inpatient	91	50	41	ND	
	[57]			NHC	2020-02-29		Inpatient	90	46	53	
	[58]			2020-02-04	Adult	Inpatient	90	50	43	7	
	[24]			RT-PCR	2020-01-23		Inpatient	81	50	52	
	[36]			2020-02-14	Adult/Children	Inpatient	80	46	49	ND	
	[47]			2020-01-15	Adult	Inpatient	78	38	50		
	[59]			Chest CT	2020-02-03	Adult/Children	Inpatient	73	42*	56	4
	[49]			2020-02-04		Inpatient	69	42	46		
	[41]			RT-PCR	2020-01-30	Adult	ND	62	53*	63	ND
	[28]			2020-01-26		Inpatient	62	41	56		

	[6]		NHC	2020-01-31		Inpatient	61	41	51	
	[39]			2020-02-18		Inpatient	56	58	55	
	[17]			2020-02-29	Adult/Children	Inpatient	55	49	40	71
	[29]			2020-01-26		ICU	52	60	67	
	[19]			2020-02-18	Adult	Inpatient	51	42	49	
	[27]			2020-01-27	Adult/Children	ND	51	49	49	
	[60]		RT-PCR	2020-02-05		Inpatient	42	50	60	ND
	[61]			2020-01-02		Inpatient	41	49	73	
	[23]			2020-01-29	Adult	Inpatient	34	56	41	
	[45]			2020-02-20		ED	32	46	47	
	[12]			2020-01-25		Inpatient	27	60	45	
	[11]			2020-02-18	Adult/Children	Outpatient	24	33	33	79
	[7]			2020-02-06		Inpatient	21	40*	26	ND
	[62]		Chest CT	2020-01-27	Adult	Inpatient	21	51*	62	10
	[34]			2020-02-05		Inpatient	19	48	40	
	[20]			ND	Adult/Children	Inpatient	19	33	42	
	[5]			2020-02-10	Adult	Inpatient	17	45	53	ND
	[15]		RT-PCR	2020-01-29		Inpatient	13	34	77	
	[22]			2020-01-20	Adult/Children	Inpatient	12	54	67	
	[63]			2020-02-06	Adult	Outpatient	11	50	73	
	[64]			ND		Outpatient	11	37	46	DNQ
	[31]			2020-01-21	Adult/Children	Outpatient	7	31*	57	ND
	[30]	Korea	KCDC criteria	2020-02-14	Adult	ND	28	ND	54	11
	[32]	Singapore	RT-PCR	2020-02-03		Inpatient	18	47	50	ND
<b>Range</b>		-	-	-	-	-	<b>[7-44 672]</b>	<b>[33-60]</b>	<b>[26-77]</b>	<b>[2-79]</b>
Europe	[13]	Belgium, Finland, France, Germany, Italy, Russia, Spain, Sweden	RT-PCR	2020-02-21	Adult/Children	ND	38	42	55	24
<b>Range</b>		-	-	-	-	-	<b>[38]</b>	<b>[42]</b>	<b>[55]</b>	<b>[24]</b>
<b>Range</b>		-	-	-	-	-	<b>[7-44 672]</b>	<b>[28-70]</b>	<b>[26-77]</b>	<b>[2-79]</b>

\*mean; DNQ: Described but not Quantified; ED: Emergency Department; ICU: Intensive Care Unit; NA: Not Applicable; ND: Not Described; NHC: National Health Commission; Ref: Reference; RT-PCR: Reverse transcription polymerase chain reaction

Table 2. Proportion of reported general, musculoskeletal symptoms, pharyngalgia and rhinorrhoea in patients with COVID-19 at baseline by continent

Ref	General symptoms					Musculoskeletal symptoms	Pharyngalgia/ Pharyngitis / Sore throat	Rhinorrhoea / Runny nose		
	Fever	Fatigue	Poor appetite/ Anorexia	Chills	Dizziness/ Drowsy	Headache			Myalgia/ Muscle Ache	
America (North)	[9]	48	17 <sup>1</sup>					30	ND	
	[14]	68	ND	ND	ND	ND	ND	DNQ	DNQ	
	[10]	52	ND					ND	ND	
<b>Range</b>	<b>[48-68]</b>	<b>[17]</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>[30]</b>	<b>DNQ</b>		
Asia	[8]	ND	ND	ND	ND	ND	ND	ND	ND	
	[25]	89	38		1	14	15 <sup>3</sup>	14	ND	
	[37]	93	46	21		8	11	21	5	2
	[54]	82	26	ND		ND	ND	ND	ND	ND
	[42]	87	16	3		11 <sup>4</sup>	11 <sup>6</sup>		6	7
	[43]	94	32 <sup>2</sup>		ND			32 <sup>4</sup>		
	[44]	94	23	ND		ND	ND	15	ND	
	[46]	ND	ND					ND		
	[26]	81	73	32		2	10	61 <sup>3</sup>		
	[21]	77	ND	ND	14	ND	9	3	14	
	[35]	92	75	12			ND	ND	ND	
	[18]	99	70	40		9	7		17	ND
	[33]	82	32 <sup>2</sup>	ND			10	32 <sup>5</sup>	ND	
	[48]	89	33 <sup>2</sup>	4			33	33 <sup>5</sup>	18	
	[55]	DNQ	ND		ND		ND	ND	ND	
	[56]	87	39	ND			13	11	13	
	[16]	78	17 <sup>2</sup>			ND	ND	17 <sup>5</sup>	12	
	[38]	83	ND				8	11	5	4
	[40]	71	44	25			ND	ND	ND	
	[57]	87	ND	ND			11	18	7	ND
	[58]	78	21		7		4	28	26	
[24]	73		1		2	6	ND	ND	26	
[36]	79	ND	ND			16	23	14	6	
[47]	DNQ			ND	ND	ND	ND	ND		
[59]	93	75	27							
[49]	19	42	10		7	14	30	9	ND	
[41]	87	23	ND		ND	ND	32	ND		

[28]	77	52 <sup>2</sup>					34	52 <sup>5</sup>		
[6]	98	57	13	20					16	
[39]	79	9					ND	ND	ND	5 <sup>7</sup>
[17]	4	ND	ND						2	ND
[29]	98						6	12	ND	6
[19]	67	4					ND	16	6	ND
[27]	96	31 <sup>2</sup>	18		16 <sup>4</sup>		16 <sup>6</sup>	31 <sup>5</sup>	6	4 <sup>7</sup>
[60]	86	33		ND			ND	ND		
[61]	98	44 <sup>2</sup>					8	44 <sup>5</sup>		
[23]	94	65 <sup>2</sup>	ND		ND		6	65 <sup>5</sup>	ND	
[45]	84	16 <sup>2</sup>					3	16 <sup>5</sup>		
[12]	78	ND						11		ND
[11]	DNQ	DNQ			DNQ		ND	ND		
[7]	86	52	43	29				24	19	
[62]	67	14				ND	14	14	ND	
[34]	79	11					11		21	
[20]	74	89		ND				ND	ND	
[5]	71	47	ND		12		ND	24	6	12
[15]	92						23	23		8
[22]	83			42	ND		0	33	ND	
[63]	73						ND	27	9	ND
[64]	DNQ	ND	DNQ	ND	DNQ	DNQ	DNQ	ND	DNQ	DNQ
[31]							ND	DNQ	ND	ND
[30]	32		ND	18	ND		11	14	32	ND
[32]	72			ND			ND	ND	61	6
<b>Range</b>	<b>[4-99]</b>	<b>[4-89]</b>	<b>[1-43]</b>	<b>[1-42]</b>	<b>[2-16]</b>	<b>[0-34]</b>	<b>[3-65]</b>	<b>[2-61]</b>	<b>[2-26]</b>	
Europe	[13]	69	ND	ND	ND	ND	21	3	7	7
<b>Range</b>	<b>69</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>ND</b>	<b>[21]</b>	<b>3</b>	<b>7</b>	<b>7</b>	
<b>Range</b>	<b>[4-99]</b>	<b>[4-89]</b>	<b>[1-43]</b>	<b>[1-42]</b>	<b>[2-16]</b>	<b>[0-34]</b>	<b>[3-65]</b>	<b>[2-61]</b>	<b>[2-26]</b>	

<sup>1</sup>: or malaise; <sup>2</sup>: or myalgia; <sup>3</sup>: or arthralgia; <sup>4</sup>: or headache; <sup>5</sup>: or fatigue; <sup>6</sup>: or dizziness; <sup>7</sup>: or nose congestion; DNQ: Described but not Quantified; ND: Not Described; Ref: Reference

Table 3. Proportion of reported respiratory symptoms in patients with COVID-19 at baseline by continent

	Reference	Respiratory symptoms				
		Cough	Cough Productive/ Expectoration/ Sputum	Dyspnoea/ Shortness of breath	Chest tightness	Chest pain
America (North)	[9]	82 <sup>1</sup>		82 <sup>2</sup>		
	[14]	90 <sup>1</sup>	ND	90 <sup>2</sup>	ND	ND
	[10]	48		76		
<b>Range</b>		<b>[48-90]</b>	<b>-</b>	<b>[76-90]</b>	<b>-</b>	<b>-</b>
Asia	[8]	ND	ND	ND		
	[25]	68	34	19		
	[37]	33	41	51		
	[54]	46		7		
	[42]	37	ND	8	ND	ND
	[43]	81		40		
	[44]	79	23			
	[46]	ND	ND	ND		
	[26]	63		32		4
	[21]	58	32	1	11	3
	[35]	75	ND	37	37	
	[18]	59	27	31		
	[33]	48	4	19	ND	
	[48]	77	9	13	9 <sup>1</sup>	ND
	[55]	DNQ	DNQ	ND		
	[56]	60				
	[16]	62	ND	1		
	[38]	82		31	ND	2
	[40]	60	33	ND		ND
	[57]	78	18	11		6
	[58]	63	12	ND		ND
	[24]	59	19	42	22	
	[36]	64		38		4
[47]	DNQ	ND	ND	ND	ND	
[59]	82	53				
[49]	55	29	29	20	9	
[41]		45	24			
[28]	81	56	ND	ND	ND	
[6]	64	44	12		2	

	[39]		38		7 <sup>3</sup>	7 <sup>1</sup>	ND
	[17]	4		ND	ND		2
	[29]	77		ND	64		ND
	[19]	45		25	8		14 <sup>1</sup>
	[27]	47		ND	14 <sup>4</sup>	ND	
	[60]	64			19		
	[61]	76		28	55		
	[23]	50		24	15		ND
	[45]	66		16	ND	9	
	[12]	59		ND	41		
	[11]	DNQ				ND	10
	[7]	57		29			
	[62]	43					
	[34]	47		ND		5	
	[20]	68			ND		
	[5]	77		18			
	[15]	46		15		ND	
	[22]	92		ND			ND
	[63]	64		27	9		
	[64]	DNQ		ND	DNQ	DNQ	
	[31]				ND		
	[30]			18		ND	
	[32]	83		ND	11		
<b>Range</b>		<b>[4-92]</b>		<b>[4-56]</b>	<b>[1-64]</b>	<b>[5-37]</b>	<b>[2-14]</b>
Europe	[13]	48		ND	7	ND	ND
<b>Range</b>		<b>[48]</b>		<b>-</b>	<b>[7]</b>	<b>-</b>	<b>-</b>
<b>Range</b>		<b>[4-92]</b>		<b>[4-56]</b>	<b>[1-90]</b>	<b>[5-37]</b>	<b>[2-14]</b>

<sup>1</sup>: or dyspnoea; <sup>2</sup>: or cough; <sup>3</sup>: or chest tightness; <sup>4</sup>: or chest pain; DNQ: Described but not Quantified; ND: Not Described; Ref: Reference

Table 4. Proportion of reported gastrointestinal symptoms in patients with COVID-19 at baseline by continent

	Reference	Gastrointestinal symptoms			
		Diarrhoea	Nausea	Vomiting/ Emesis	Abdominal distress
America (North)	[9]				
	[14]	ND	ND	ND	ND
	[10]				
<b>Range</b>		-	-	-	-
Asia	[8]	ND	ND	ND	ND
	[25]	4		5	
	[37]	27		9	5
	[54]	ND			
	[42]	3		ND	
	[43]	ND			ND
	[44]	5		4	
	[46]	ND		ND	
	[26]	5		4	2
	[21]	7		1	ND
	[35]	13	17	5	6
	[18]	10	10	4	2
	[33]	8		ND	
	[48]	13	ND	3	
	[55]	ND		ND	ND
	[56]	14			
	[16]	3		2	
	[38]	2		1	
	[40]	23	12	7	1
	[57]	8 <sup>1</sup>	ND	ND	8 <sup>2</sup>
	[58]	6	6	2	
	[24]	4	ND	5	
	[36]	1		1	ND
	[47]	ND		ND	
	[59]				
	[49]	14	ND	4	
	[41]	15 <sup>1</sup>		ND	15 <sup>2</sup>
[28]	8				
[6]	10		8	ND	
[39]	ND	ND	18		



[17]				ND
[29]				4
[19]	10			ND
[27]	10		6	
[60]	24			
[61]	3			
[23]	15			
[45]	3	ND		
[12]				
[11]	ND			ND
[7]				
[62]		5		
[34]	5			
[20]	16			
[5]	12	ND		
[15]	8			
[22]	17		17	
[63]	9			
[64]	DNQ			
[31]	ND	ND		ND
[30]				
[32]	17			
<b>Range</b>	<b>[1-27]</b>	<b>[1-17]</b>	<b>[1-18]</b>	<b>[1-15]</b>
Europe	[13]	3	3	ND
<b>Range</b>	<b>[3]</b>	<b>[3]</b>	<b>-</b>	<b>-</b>
<b>Range</b>	<b>[1-27]</b>	<b>[1-17]</b>	<b>[1-18]</b>	<b>[1-15]</b>

<sup>1</sup>: or dyspnoea; <sup>2</sup>: or cough; <sup>3</sup>: or chest tightness; <sup>4</sup>: or chest pain; DNQ: Described but not Quantified; ND: Not Described; Ref: Reference

Table 5. Proportion of co-morbidities in patients with COVID-19 at baseline by continent

	Ref	Malignancy	Endocrine system	Renal system	Neurological system	Cardiovascular system		Respiratory system				
			Diabetes	Kidney disease	CKD	Cerebrovascular disease	Cardiovascular disease	Hypertension	Respiratory disease	Pulmonary disease	COPD	
America (North)	[9]											
	[14]	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
	[10]		33		48						33	
<b>Range</b>		-	<b>33</b>	-	<b>48</b>	-	-	-	-	-	<b>33</b>	
Asia	[8]	ND	7	ND		ND	11	6	6		ND	
	[25]		7	1		1	3	15			1	
	[37]	3	16	2		2	6	30	ND	ND	3	
	[54]	ND	ND			ND	ND					
	[42]	0	10	ND	ND	22 <sup>1</sup>	22 <sup>2</sup>	ND	2			
	[43]	ND	5		ND		3	14			ND	
	[44]	1	19	1		ND	8	30		3		
	[46]	ND	ND	ND		DNQ	DNQ	0				
	[26]	5	10	4		5	10	24			3	
	[21]		ND				ND	ND			ND	
	[35]	ND	12	ND	1	ND	5	30	ND	ND	1	
	[18]	7	10	3		5	15	31			3	
	[33]	2	10					7	10		2	
	[48]	3	9					5	10		1	
	[55]					ND					0	
	[56]	ND	ND		ND		ND					
	[16]				ND		16 <sup>1</sup>	16 <sup>2</sup>	ND	5		ND
	[38]	1					40 <sup>1</sup>	40 <sup>2</sup>		1		
	[40]			9			3 <sup>1</sup>	3 <sup>2</sup>	17			
	[57]	ND		8			ND	1	6	ND	ND	6
	[58]	2		6				3	19			1
	[24]	5		12		4	7	10	15			11
	[36]	1		ND	1		31	31	ND	1		0
[47]			25					40			10	
[59]			ND	ND	ND	ND	ND	ND			ND	
[49]	ND		10				12	13	ND	10	6	
[41]			7	2				7		ND	ND	
[28]			2	2		2	ND	8		ND	2	

[6]		8	ND			2	20			8
[39]		7	3		ND	11	18			
[17]		ND	ND			ND	15			
[29]	4	17			14	10	ND		8	ND
[19]		8	6			10			5	
[27]	ND	6				2	10			2
[60]		DNQ			ND	DNQ	DNQ		ND	ND
[61]	2	20				15	15			2
[23]	9	12				18	24		6	3
[45]	6	13		3	13	6	22			6
[12]		22			4	11	19	41		
[11]		DNQ					DNQ			
[7]							ND			
[62]							11			
[34]		ND	ND	ND		ND				ND
[20]							6		ND	
[5]	ND						ND	ND		
[15]					ND					
[22]		17		17		33	25			
[63]						ND	ND			
[64]						DNQ	DNQ			DNQ
[31]		ND		ND						
[30]						ND	ND			ND
[32]										
<b>Range</b>	<b>[0-9]</b>	<b>[2-25]</b>	<b>[1-6]</b>	<b>[1-17]</b>	<b>[1-40]</b>	<b>[1-40]</b>	<b>[0-40]</b>	<b>[1-41]</b>	<b>[1-10]</b>	<b>[0-11]</b>
Europe	[13]	ND	ND	ND	ND	ND	ND	ND	ND	ND
<b>Range</b>	-	-	-	-	-	-	-	-	-	-
<b>Range</b>	<b>[0-9]</b>	<b>[2-33]</b>	<b>[1-6]</b>	<b>[0-48]</b>	<b>[1-40]</b>	<b>[1-40]</b>	<b>[0-40]</b>	<b>[1-41]</b>	<b>[1-10]</b>	<b>[0-33]</b>

<sup>1</sup>: or cardiovascular disease; <sup>2</sup>: or cerebrovascular disease; CKD: Chronic Kidney Disease; COPD: Chronic Obstructive Pulmonary Disease; DNQ: Described but not Quantified; ND: Not Described; Ref: Reference